Author response for "Cardiovascular and renal outcomes by baseline albuminuria status and renal function — results from the <scp>LEADER</scp> randomized trial"

Ofri Mosenzon(Hebrew University of Jerusalem), Itamar Raz(Hebrew University of Jerusalem), Bernt Johan von Scholten(Novo Nordisk (Denmark)), Johannes F.E. Mann(Katholische Stiftungshochschule München), Stephen C. Bain(Swansea University), Hiddo J.L. Heerspink(University Medical Center Groningen), Peter Rossing(Steno Diabetes Centers), Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Søren Rasmussen, Thomas Idorn(University of Copenhagen), Frederik Persson
Unknown
June 19, 2020
10.1111/dom.14126/v2/response1
Cited by 0

Related Papers

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k